Cann Reaffirms Outperform Rating for Amgen, Inc.
Several other analysts have also commented on AMGN. Argus set a $195.00 price target on shares of Amgen and gave the company a "buy" rating in a research report on Saturday, February 11th.
from Biotech News
0 Comments